Abstracts tagged "longitudinal studies"

Abstract Number: 2514 • 2012 ACR/ARHP Annual Meeting
Racial/Ethnic Trends in Incidence and Prevalence of Rheumatoid Arthritis in a Large Multi-Ethnic Managed Care Population
Aniket A. Kawatkar¹, Cecilia Portugal¹, Li-Hao Chu² and Rajan Iyer³, ¹Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, ²Department of Research and Evaluation,, Kaiser Permanente Southern California, Pasadena, ³Department of Research and Evaluation,, Kaiser Permanente Southern California, Pasadena, CA
Background/Purpose: As epidemiologic studies throughout the world have shown significant variations, we sought to characterize racial differences in longitudinal epidemiologic trends of adult rheumatoid arthritis…
Abstract Number: 448 • 2012 ACR/ARHP Annual Meeting
Sustained and Cumulated Response Over Time in Rheumatoid Arthritis Patients Treated with Rituximab After Initial Failure of Anti Tumor Necrosis Factor Agents
Ioan Ancuta¹, Catalin Codreanu², Ruxandra Ionescu³, Magda Parvu⁴ and Mihai Bojinca⁵, ¹Internal Medicine, Cantacuzino Hospital, Bucharest, Romania, ²Rheumatology, “Dr. I. Stoia” Center for Rheumatic Diseases, Bucharest, Romania, ³Clinic Hospital "Sf. Maria", Bucharest, Romania, ⁴Internal Medicine, “N.Gh. Lupu” Clinical Hospital, Bucharest, Romania, ⁵Internal Medicine, “Dr. I. Cantacuzino” Hospital, Bucharest, Romania
Background/Purpose: Although anti-TNF therapies moved forward the treatment of rheumatoid arthritis (RA), failure of the first anti-TNF medication is not uncommon. Many times modifying dosage/frequency…
Abstract Number: 2490 • 2012 ACR/ARHP Annual Meeting
Herpes Zoster and Tofacitinib Therapy in Patients with Rheumatoid Arthritis
K. L. Winthrop¹, H. Valdez², E. Mortensen³, R. Chew⁴, S. Krishnaswami⁵, T. Kawabata⁵ and R. Riese⁴, ¹Division of Infectious Diseases, Oregon Health and Science University, Portland, OR, ²Pfizer Inc., New York, NY, ³Global Medical Affairs, Pfizer Inc., Collegeville, PA, ⁴Pfizer Inc., Groton, CT, ⁵Pfizer Inc, Groton, CT
Background/Purpose: Patients (pts) with RA are at increased risk for herpes zoster (HZ) i.e. ‘shingles'. Tofacitinib, a novel oral Janus kinase inhibitor investigated as a…
Abstract Number: 449 • 2012 ACR/ARHP Annual Meeting
Rituximab After First Anti Tumor Necrosis Factor Failure Is More Efficient with High Impact in Reducing Time and Costs to Achieve Superior Rates of Low Disease Activity and Remission
Ioan Ancuta¹, Catalin Codreanu², Ruxandra Ionescu³, Magda Parvu⁴ and Mihai Bojinca¹, ¹Internal Medicine, “Dr. I. Cantacuzino” Hospital, Bucharest, Romania, ²Rheumatology, “Dr. I. Stoia” Center for Rheumatic Diseases, Bucharest, Romania, ³Internal Medicine, Clinic Hospital Sf. Maria, Bucharest, Romania, ⁴Internal Medicine, “N.Gh. Lupu” Clinical Hospital, Bucharest, Romania
Background/Purpose: Significant steps were done in creating new medications for treatment of rheumatoid arthritis (RA). As RA seriously affects the patients’ quality of life, the…
Abstract Number: 2469 • 2012 ACR/ARHP Annual Meeting
A Virtual Knee Joint Replacement Clinical Endpoint Based On Longitudinal Trends and Thresholds in Koos Knee Pain and Function in Osteoarthritis Initiative Participants
Robert M. Boudreau¹, David J. Hunter², Zhijie Wang³, Frank Roemer⁴, Felix Eckstein⁵, Michael J. Hannon³, Ali Guermazi⁶ and C. Kent Kwoh⁷, ¹Epidemiology, University of Pittsburgh, Pittsburgh, PA, ²Rheumatology, Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, Australia, ³Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁴Radiology, Boston University School of Medicine, Boston, MA, ⁵Anatomy & Musculoskeletal Research, Paracelsus Medical University, Salzburg, Austria, ⁶Boston University, Boston, MA, ⁷School of Medicine, Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Knee joint replacement (KR) is a cost-effective procedure with good long-term outcomes, but has limitations as an endpoint in OA intervention trials. A definition…
Abstract Number: 390 • 2012 ACR/ARHP Annual Meeting
Performance of Criteria for Remission in a Long-Term Observational Study of Patients with Early Rheumatoid Arthritis
Bjorn Svensson¹, Maria LE Andersson², Sidona-Valentina Bala³, Kristina Forslind⁴ and Ingiäld Hafström⁵, ¹Section of Rheumatology, Institution of Clinical Science, Lund University, Lund, Sweden, ²R&D Center, Spenshult Hospital, Oskarström, Sweden, ³Department of Health Sciences,, Lund University, Lund, Sweden, ⁴Department of Medicine, Karolinska Institute, Stockholm, Department of Medicine, Karolinska Institute,, Stockholm, Sweden, ⁵Unit of Rheumatology, Department of Medicine, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Remission is widely accepted as the goal of treatment in RA and has to be sustained to keep joint damage at a minimum (Smolen…
Abstract Number: 2158 • 2012 ACR/ARHP Annual Meeting
Baseline Folate Related Biomarkers in Serum and erythrocytes Are Not Associated with Methotrexate Response and Adverse Events in Rheumatoid Arthritis
Maurits C.F.J. De Rotte¹, Saskia M.F. Pluijm², Maja Bulatovic³, Johanna M.W. Hazes⁴ and Robert De Jonge¹, ¹Clinical Chemistry, Erasmus Medical Center, Rotterdam, Netherlands, ²Public Health, Erasmus Medical center, Rotterdam, Netherlands, ³Department of Paediatric Immunology, University Medical Centre Utrecht, Netherlands, ⁴Rheumatology, Erasmus MC, Rotterdam, Netherlands
Background/Purpose: Methotrexate (MTX) is the most commonly used drug in rheumatoid arthritis (RA). 30% of patients fail to respond to the drug or suffer from…
Abstract Number: 232 • 2012 ACR/ARHP Annual Meeting
The Natural History of Sporadic Inclusion Body Myositis – an Observational Longitudinal Study
Pedro Machado¹, Andrea Cortese¹, Jasper Morrow¹, Liz Dewar¹, Andy Hiscock¹, Adrian Miller¹, Stefen Brady², David Hilton-Jones², Matt Parton¹ and Michael G. Hanna¹, ¹MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology, London, United Kingdom, ²Oxford Muscle and Nerve Centre, John Radcliffe Hospital, Oxford, United Kingdom
Background/Purpose: Our aim was to assess prospectively the clinical features and functional impact of inclusion body myositis (IBM), to identify reliable outcome measures for future…
Abstract Number: 2161 • 2012 ACR/ARHP Annual Meeting
Methotrexate Polyglutamate Concentrations in Erythrocytes Are a Potential Tool for Therapeutic Drug Monitoring of Methotrexate Response in Rheumatoid Arthritis
Maurits C.F.J. De Rotte¹, Ethan den Boer², Maja Bulatovic³, Saskia M.F. Pluijm⁴, Johanna M.W. Hazes⁵ and Robert De Jonge¹, ¹Clinical Chemistry, Erasmus Medical Center, Rotterdam, Netherlands, ²Clinical Chemistry, Erasmus University Hospital, Rotterdam, Netherlands, ³Department of Paediatric Immunology, University Medical Centre Utrecht, Netherlands, ⁴Public Health, Erasmus Medical center, Rotterdam, Netherlands, ⁵Rheumatology, Erasmus MC, Rotterdam, Netherlands
Background/Purpose: Methotrexate (MTX) is the most commonly used drug in rheumatoid arthritis (RA). 30% of patients fail to respond to the drug or suffer from…
Abstract Number: 2134 • 2012 ACR/ARHP Annual Meeting
The Changed Prognosis of Patients with Early Rheumatoid Arthritis
Karin Britsemmer¹ and Dirkjan van Schaardenburg², ¹Rheumatology, Jan van Breemen Research Institute / Reade, Amsterdam, Netherlands, ²Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands
The Changed Prognosis of Patients with Early Rheumatoid Arthritis Background/Purpose: The treatment of rheumatoid arthritis (RA) has changed greatly during the past fifteen to twenty…
Abstract Number: 2068 • 2012 ACR/ARHP Annual Meeting
Is There a Difference in Rheumatology Patient Reported Outcomes When Measured At Home Versus the Clinic Setting?
C.J. Inman¹, Frederick Wolfe² and Kaleb Michaud³, ¹Pediatric Administration, University of Utah, Salt Lake City, UT, ²National Data Bank for Rheumatic Diseases, Wichita, KS, ³Rheumatology, National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Registries have become a common tool for collecting patient-centered outcome measures. Clinical effectiveness research may be improved if data from multiple registries could be…
Abstract Number: 1587 • 2012 ACR/ARHP Annual Meeting
Despite Low Disease Activity Patients with Poly- and Dermatomyositis Perceive Activity Limitation, Reduced Grip Force and Quality of Life Longitudinally
Malin Regardt¹, Marie-Louise Schult², Ingrid E. Lundberg³ and Elisabet MB Welin Henriksson⁴, ¹Department of Occupational Therapy, Department of Neurobiology, Care Sciences and Society, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ²Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet., Stockholm, Sweden, ³Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ⁴Medicine, Karolinska Institutet Rheum, Stockholm, Sweden
Background/Purpose: Polymyositis (PM) and dermatomyositis (DM) are characterized by proximal muscle weakness. A recent study has shown that patients with PM and DM have reduced…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].